Evidence map›Paper›PMID 41599703›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

Tumor Characterization Using [

Bernadett Erzsébet Kálmán, Agnieszka Bos-Liedke, Dániel Dezső, Ewelina Kaminska, Mateusz Matusewicz, Ferenc Budán, Domokos Mathe, János Girán, Dávid Sipos, Éva Pusztai and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bernadett Erzsébet KálmánDepartment of Medical Imaging, Medical School, University of Pécs, 7621 Pécs, Hungary.ORCID 0009-0002-8577-5747
Agnieszka Bos-LiedkeDepartment of Biomedical Physics, Adam Mickiewicz University, Uniwersytetu Poznanskiego 2, 61-614 Poznan, Poland.ORCID 0000-0002-4009-0501
Dániel DezsőDepartment of Medical Imaging, Medical School, University of Pécs, 7621 Pécs, Hungary.ORCID 0000-0002-2481-2228
Ewelina KaminskaHealthQuest Sp. z o.o. Adama Mickiewicza 63, 01-625 Warszawa, Poland.ORCID 0009-0009-0635-8322
Mateusz MatusewiczFaculty of Economics, University of Life Science, 60-637 Poznan, Poland.
Ferenc BudánInstitute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.ORCID 0000-0003-1562-9496
Domokos MatheDepartment of Biophysics and Radiation Biology, Semmelweis University, 1094 Budapest, Hungary.ORCID 0000-0001-7343-0413
János GiránDepartment of Public Health Medicine, Medical School, University of Pécs, Szigeti Street 12, 7624 Pécs, Hungary.ORCID 0000-0002-4309-0013
Dávid SiposDepartment of Medical Imaging, Faculty of Health Sciences, University of Pécs, 7621 Pécs, Hungary.ORCID 0000-0001-9615-1740
Éva PusztaiDepartment of Oncotherapy, University of Pécs Clinical Center, Édesanyák Street 17, 7624 Pécs, Hungary.
Árpád BoronkaiDepartment of Oncotherapy, University of Pécs Clinical Center, Édesanyák Street 17, 7624 Pécs, Hungary.
Zsombor RitterDepartment of Medical Imaging, Medical School, University of Pécs, 7621 Pécs, Hungary.ORCID 0000-0002-2898-1571

Funding

Ministry of Culture and Innovation of Hungary TKP2021-EGA-10Research Grant Hungary RGH 151414
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

durvalumabFDGNLRNSCLCPD-L1PET-CTradiomicsstage III

Identifiers

PMID41599703
PMCPMC12844887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.